Stock BMY BRISTOL-MYERS SQUIBB COMPANY
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Bristol-Myers Squibb Company Swiss Exchange

Equities

BMY

US1101221083

Market Closed - Swiss Exchange
Other stock markets
 11:35:20 2019-06-28 EDT 		5-day change 1st Jan Change
44.39 CHF -0.25% Intraday chart for Bristol-Myers Squibb Company -18.16% -18.16%
06:28pm Top Midday Stories: Southwest Cuts Q2 Guidance; HHS to Lower Costs for Medicare Enrollees on 64 Drugs; Bosch Weighing Acquisition Offer for Whirlpool; Novo Nordisk to Record $816.2 Million Impairment MT
05:27pm Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees MT

Other languages

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Top Midday Stories: Southwest Cuts Q2 Guidance; HHS to Lower Costs for Medicare Enrollees on 64 Drugs; Bosch Weighing Acquisition Offer for Whirlpool; Novo Nordisk to Record $816.2 Million Impairment
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees
Biden Administration to Lower Costs for 64 Prescription Drugs for Medicare Enrollees
Bristol Myers : approbation accélérée en cancer colorectal
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI®? in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer
Bristol-Myers Squibb's Colorectal Cancer Therapy Receives FDA Approval
US FDA approves Bristol Myers' colorectal cancer therapy
Bristol-Myers Squibb Says EMA Validates Application for Subcutaneous Opdivo
Bristol Myers : demande validée pour Opdivo sous-cutané
Bristol Myers Squibb Announces European Medicines Agency Validates Extension Application to Introduce New Route of Administration (Subcutaneous Use) for Opdivo
Bristol Myers : l'ex-CEO d'Agilent rejoint le conseil
Bristol Myers Squibb Appoints Michael R. McMullen as Independent Director and Member of the Audit Committee, Effective July 1, 2024
Immunocore Randomizes First Patient in Phase 3 Trial of Cutaneous Melanoma Combination Treatment
Bristol Myers : dividendes décidés par le conseil
Bristol Myers Squibb Declares A Quarterly Dividend, Payable on August 1, 2024
Bristol Myers : approbation de la FDA pour un traitement
Bristol-Myers Squibb's Augtyro Gets FDA Accelerated Approval for Treatment of Solid Tumors
Bristol Myers Squibb Announces U.S. Food and Drug Administration Approves Augtyro (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
Evotec to Receive $20 Million Under Neuroscience Partnership with Bristol Myers Squibb
Evotec Gets $20 Million Milestone Payment in Neurodegenerative Disease Collaboration With Bristol Myers Squibb
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. BMY Stock
  4. BMY Stock
  5. News Bristol-Myers Squibb Company
  6. Other languages